[GRAPHIC OMITTED] [GRAPHIC OMITTED]


MEDIA/INVESTORS CONTACT:
Brian Korb
The Trout Group
(212) 477-9007 x23

             CYTOGEN ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER

PRINCETON,  N.J., (June 20, 2006) -- Cytogen  Corporation  (NASDAQ:  CYTO) today
announced  that  Christopher  P.  Schnittker,  senior vice  president  and chief
financial  officer,  has resigned from Cytogen effective June 20, 2006 to pursue
other  career  opportunities.  The  Company  has  initiated  a  search  for  Mr.
Schnittker's successor.

Ms. Thu Dang, vice president of finance,  will continue to handle the day-to-day
financial  matters of the Company until a replacement  has been found.  Ms. Dang
has been with Cytogen for more than fifteen years and is integrally  involved in
all aspects of the Company's financial reporting process.

"We  appreciate  Chris'  contributions  to  Cytogen  and we wish him well in his
future endeavors," said Michael D. Becker, president and chief executive officer
of Cytogen. "We are confident that Thu Dang, our vice president of finance, will
facilitate a smooth  transition while we search for a new CFO who as part of the
Cytogen  leadership  team can continue the  Company's  track record of financial
strength and commercial growth."

ABOUT CYTOGEN CORPORATION
-------------------------

Founded in 1980, Cytogen  Corporation of Princeton,  NJ, is a  biopharmaceutical
company  dedicated to improving  the lives of patients with cancer by acquiring,
developing  and  commercializing  innovative  molecules  targeting the sites and
stages of cancer progression.  Cytogen's marketed products include  QUADRAMET(R)
(samarium Sm-153 lexidronam injection),  PROSTASCINT(R) (capromab pendetide) kit
for the  preparation  of Indium  In-111  capromab  pendetide,  and  SOLTAMOX(TM)
(tamoxifen  citrate,  oral solution  10mg/5mL) in the United  States.  Cytogen's
development  pipeline consists of CYT-500, a therapeutic  radiolabeled  antibody
targeting  prostate-specific membrane antigen (PSMA), a protein highly expressed
on the surface of prostate cancer cells and the  neovasculature of solid tumors.
Cytogen  also has  exclusive  United  States  marketing  rights  to  COMBIDEX(R)
(ferumoxtran-10)  for all  applications,  and the exclusive  right to market and
sell ferumoxytol  (previously Code 7228) for oncology applications in the United
States. Full prescribing  information for the Company's products is available at
www.cytogen.com or by calling 800-833-3533.  For more information,  please visit
the  Company's  website  at  www.cytogen.com,  which is not  part of this  press
release.

This press release  contains  certain  "forward-looking"  statements  within the
meaning of the Private Securities  Litigation Reform Act of 1995 and Section 21E
of the Securities Exchange Act of 1934, as amended.  All statements,  other than
statements of  historical  facts,  included in this press release  regarding our
strategy,  future operations,  financial  position,  future revenues,  projected
costs,  prospects,  plans  and  objectives  of  management  are  forward-looking
statements.  Such  forward-looking  statements  involve  a number  of risks  and
uncertainties  and investors are cautioned not to put any undue  reliance on any
forward-looking  statement.  There are a number of important  factors that could
cause  Cytogen's  results  to differ  materially  from those  indicated  by such
forward-looking  statements.  In particular,  Cytogen's business is subject to a
number of significant risks, which include,  but are not limited to: the risk of
obtaining  the  necessary  regulatory  approvals;  the risk of whether  products
result  from  development  activities;  the  risk of  shifts  in the  regulatory
environment  affecting  sales of Cytogen's  products such as  third-party  payor
reimbursement  issues;  the risk  associated  with  Cytogen's  dependence on its
partners for development of certain projects, as well as other factors expressed
from time to time in Cytogen's periodic filings with the Securities and Exchange
Commission  (the  "SEC").  As a result,  this  press  release  should be read in
conjunction with Cytogen's periodic filings with the SEC.  The forward-looking





statements  contained herein are made only as of the date of this press release,
and Cytogen  undertakes no obligation  to publicly  update such  forward-looking
statements to reflect subsequent events or circumstances.

                                       ###